<DOC>
	<DOCNO>NCT00412412</DOCNO>
	<brief_summary>The goal clinical research study study drug CNF2024 single agent combination trastuzumab patient advanced breast cancer : - find high dose drug CNF2024 single agent combination trastuzumab give safely - measure level CNF2024 single agent combination trastuzumab blood - determine CNF2024 single agent combination trastuzumab stop breast cancer cell grow</brief_summary>
	<brief_title>CNF2024 ( BIIB021 ) HER2- ( QD ) HER2+ ( BIW w/Herceptin ) PK/PD Study</brief_title>
	<detailed_description>A Phase 1 Open-Label , Dose-Escalation , Safety , Pharmacokinetic , Pharmacodynamic Study CNF2024 Single-Agent Treatment Subjects HER2- Advanced Breast Cancer Combination Trastuzumab Subjects HER2+ Advanced Breast Cancer</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Inclusion Criteria ( Group A ) : Age ≥18 year time inform consent . Male female subject confirm HER2 adenocarcinoma breast advanced disease ( advanced disease define metastatic disease locally advanced disease surgically unresectable consider unmanageable standard therapy radiation systemic therapy ) disease progression least one standard hormonal chemotherapy regimen advance breast cancer refuse standard therapy . Evaluable disease either measurable disease ( RECIST ) nonmeasurable disease . ECOG ≤2 . Required Laboratory Values : ANC ≥1500 cells/mm3 , platelet count ≥100,000 cells/mm3 , hemoglobin ≥9 gm/L ; Glucose &gt; 3.3 mmol/L , sodium &gt; 130 mmol/L , calcium &gt; 2.0 mmol/L . Plasma cortisol ACTH level suggestive adrenal insufficiency . Normal electrocardiogram ( ECG ) QTc ≤450 msec men ≤470 msec woman . Female subject childbearing potential must negative pregnancy test within 7 day prior first study drug administration . Inclusion Criteria ( Group B ) : Age ≥18 year time inform consent . Male female subject confirm HER2+ ( IHC 3+ IHC 2+/FISH+ ) adenocarcinoma breast advance disease disease progression least 1 standard hormonal chemotherapy regimen advance metastatic breast cancer . Advanced disease define metastatic disease locally advanced disease surgically unresectable consider unmanageable standard therapy radiation systemic therapy . Subjects must progress either within 3 month follow last dose adjuvant trastuzumab treatment progress follow trastuzumab base therapy metastatic disease . Measurable disease RECIST evaluable nonmeasurable disease ECOG ≤2 . Required Laboratory Values : ANC ≥1500 cells/mm3 , platelet count ≥100,000 cells/mm3 , hemoglobin ≥9 gm/L ; Glucose &gt; 3.3 mmol/L , sodium &gt; 130 mmol/L , calcium &gt; 2.0 mmol/L . Plasma cortisol ACTH level suggestive adrenal insufficiency . Normal ECG QTc ≤450 msec men ≤470 msec woman . Female subject childbearing potential must negative pregnancy test within 7 day prior first study drug administration . Exclusion Criteria ( Group A ) : Prior antitumor therapy include prior experimental agent approve antitumor therapy , within 1 month . Active infection require intravenous ( IV ) antibiotic treatment . History prior malignancy within past 5 year exception curatively treat basal squamous cell carcinoma skin carcinoma situ cervix . Concurrent severe uncontrolled diabetes and/or medical disease Problems swallow malabsorption . History major surgery small intestine . Prior treatment Hsp90 inhibitor . History central nervous system ( CNS ) metastasis . Exclusion Criteria ( Group B ) : Prior antitumor therapy , include prior experimental agent approve antitumor therapy , within 1 month . Active infection require intravenous ( IV ) antibiotic treatment . History prior malignancy within past 5 year exception curatively treat basal squamous cell carcinoma skin carcinoma situ cervix . Concurrent severe uncontrolled diabetes and/or medical disease Problems swallow malabsorption . History major surgery small intestine . Cardiac leave ventricular function rest ejection fraction &lt; 50 % , assess either ECHO MUGA . Prior treatment Hsp90 inhibitor . Diabetes treat insulin . History CNS metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Cancer Breast</keyword>
	<keyword>Cancer Breast</keyword>
</DOC>